1mu9 › Citations

Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures.

Davies DR, Interthal H, Champoux JJ, Hol WG
J Mol Biol 324 917-32 (2002)
Cited: 77 times
EuropePMC logo PMID: 12470949

Abstract

Tyrosyl-DNA phosphodiesterase (Tdp1) is a DNA repair enzyme that catalyzes the hydrolysis of a phosphodiester bond between a tyrosine residue and a DNA 3'-phosphate. The only known example of such a linkage in eukaryotic cells occurs normally as a transient link between a type IB topoisomerase and DNA. Thus human Tdp1 is thought to be responsible for repairing lesions that occur when topoisomerase I becomes stalled on the DNA in the cell. Tdp1 has also been shown to remove glycolate from single-stranded DNA containing a 3'-phosphoglycolate, suggesting a role for Tdp1 in repair of free-radical mediated DNA double-strand breaks. We report the three-dimensional structures of human Tdp1 bound to the phosphate transition state analogs vanadate and tungstate. Each structure shows the inhibitor covalently bound to His263, confirming that this residue is the nucleophile in the first step of the catalytic reaction. Vanadate in the Tdp1-vanadate structure has a trigonal bipyramidal geometry that mimics the transition state for hydrolysis of a phosphodiester bond, while Tdp1-tungstate displays unusual octahedral coordination. The presence of low-occupancy tungstate molecules along the narrow groove of the substrate binding cleft is suggestive evidence that this groove binds ssDNA. In both cases, glycerol from the cryoprotectant solution became liganded to the vanadate or tungstate inhibitor molecules in a bidentate 1,2-diol fashion. These structural models allow predictions to be made regarding the specific binding mode of the substrate and the mechanism of catalysis.

Articles - 1mu9 mentioned but not cited (1)

  1. Structure Modeling of Human Tyrosyl-DNA Phosphodiesterase 1 and Screening for Its Inhibitors. Gushchina IV, Nilov DK, Zakharenko AL, Lavrik OI, Švedas VK. Acta Naturae 9 59-66 (2017)


Reviews citing this publication (12)

  1. Drugging topoisomerases: lessons and challenges. Pommier Y. ACS Chem Biol 8 82-95 (2013)
  2. Defective DNA repair and neurodegenerative disease. Rass U, Ahel I, West SC. Cell 130 991-1004 (2007)
  3. Phospholipase D: enzymology, functionality, and chemical modulation. Selvy PE, Lavieri RR, Lindsley CW, Brown HA. Chem Rev 111 6064-6119 (2011)
  4. Repair of topoisomerase I-mediated DNA damage. Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, Agama K, Nitiss JL, Redon C. Prog Nucleic Acid Res Mol Biol 81 179-229 (2006)
  5. Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. Dexheimer TS, Antony S, Marchand C, Pommier Y. Anticancer Agents Med Chem 8 381-389 (2008)
  6. The power of vanadate in crystallographic investigations of phosphoryl transfer enzymes. Davies DR, Hol WG. FEBS Lett 577 315-321 (2004)
  7. Repair of DNA covalently linked to protein. Connelly JC, Leach DR. Mol Cell 13 307-316 (2004)
  8. Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors. Huang SN, Pommier Y, Marchand C. Expert Opin Ther Pat 21 1285-1292 (2011)
  9. Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC). Sun Y, Saha S, Wang W, Saha LK, Huang SN, Pommier Y. DNA Repair (Amst) 89 102837 (2020)
  10. Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target. Comeaux EQ, van Waardenburg RC. Drug Metab Rev 46 494-507 (2014)
  11. Mammalian phospholipase D: Function, and therapeutics. McDermott MI, Wang Y, Wakelam MJO, Bankaitis VA. Prog Lipid Res 78 101018 (2020)
  12. Natural Products and Their Derivatives as Inhibitors of the DNA Repair Enzyme Tyrosyl-DNA Phosphodiesterase 1. Zakharenko AL, Luzina OA, Chepanova AA, Dyrkheeva NS, Salakhutdinov NF, Lavrik OI. Int J Mol Sci 24 5781 (2023)

Articles citing this publication (64)

  1. Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. Interthal H, Chen HJ, Champoux JJ. J Biol Chem 280 36518-36528 (2005)
  2. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. Nitiss KC, Malik M, He X, White SW, Nitiss JL. Proc Natl Acad Sci U S A 103 8953-8958 (2006)
  3. Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. Davies DR, Interthal H, Champoux JJ, Hol WG. Chem Biol 10 139-147 (2003)
  4. Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1. Antony S, Marchand C, Stephen AG, Thibaut L, Agama KK, Fisher RJ, Pommier Y. Nucleic Acids Res 35 4474-4484 (2007)
  5. The reaction mechanism of phospholipase D from Streptomyces sp. strain PMF. Snapshots along the reaction pathway reveal a pentacoordinate reaction intermediate and an unexpected final product. Leiros I, McSweeney S, Hough E. J Mol Biol 339 805-820 (2004)
  6. Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay. Marchand C, Lea WA, Jadhav A, Dexheimer TS, Austin CP, Inglese J, Pommier Y, Simeonov A. Mol Cancer Ther 8 240-248 (2009)
  7. SUMO modification of the neuroprotective protein TDP1 facilitates chromosomal single-strand break repair. Hudson JJ, Chiang SC, Wells OS, Rookyard C, El-Khamisy SF. Nat Commun 3 733 (2012)
  8. Analysis of human tyrosyl-DNA phosphodiesterase I catalytic residues. Raymond AC, Rideout MC, Staker B, Hjerrild K, Burgin AB. J Mol Biol 338 895-906 (2004)
  9. Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Liu C, Zhou S, Begum S, Sidransky D, Westra WH, Brock M, Califano JA. Lung Cancer 55 303-311 (2007)
  10. 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors. Dexheimer TS, Gediya LK, Stephen AG, Weidlich I, Antony S, Marchand C, Interthal H, Nicklaus M, Fisher RJ, Njar VC, Pommier Y. J Med Chem 52 7122-7131 (2009)
  11. Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors. Liao Z, Thibaut L, Jobson A, Pommier Y. Mol Pharmacol 70 366-372 (2006)
  12. Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors. Nguyen TX, Morrell A, Conda-Sheridan M, Marchand C, Agama K, Bermingham A, Bermingam A, Stephen AG, Chergui A, Naumova A, Fisher R, O'Keefe BR, Pommier Y, Cushman M. J Med Chem 55 4457-4478 (2012)
  13. The catalytic scaffold of the haloalkanoic acid dehalogenase enzyme superfamily acts as a mold for the trigonal bipyramidal transition state. Lu Z, Dunaway-Mariano D, Allen KN. Proc Natl Acad Sci U S A 105 5687-5692 (2008)
  14. Effects of DNA and protein size on substrate cleavage by human tyrosyl-DNA phosphodiesterase 1. Interthal H, Champoux JJ. Biochem J 436 559-566 (2011)
  15. Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1). Conda-Sheridan M, Reddy PV, Morrell A, Cobb BT, Marchand C, Agama K, Chergui A, Renaud A, Stephen AG, Bindu LK, Pommier Y, Cushman M. J Med Chem 56 182-200 (2013)
  16. The role of TDP1 from budding yeast in the repair of DNA damage. Liu C, Pouliot JJ, Nash HA. DNA Repair (Amst) 3 593-601 (2004)
  17. Promising New Inhibitors of Tyrosyl-DNA Phosphodiesterase I (Tdp 1) Combining 4-Arylcoumarin and Monoterpenoid Moieties as Components of Complex Antitumor Therapy. Khomenko TM, Zakharenko AL, Chepanova AA, Ilina ES, Zakharova OD, Kaledin VI, Nikolin VP, Popova NA, Korchagina DV, Reynisson J, Chand R, Ayine-Tora DM, Patel J, Leung IKH, Volcho KP, Salakhutdinov NF, Lavrik OI. Int J Mol Sci 21 E126 (2019)
  18. Tyrosyl-DNA phosphodiesterase 1 initiates repair of apurinic/apyrimidinic sites. Lebedeva NA, Rechkunova NI, El-Khamisy SF, Lavrik OI. Biochimie 94 1749-1753 (2012)
  19. Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2). Wang P, Elsayed MSA, Plescia CB, Ravji A, Redon CE, Kiselev E, Marchand C, Zeleznik O, Agama K, Pommier Y, Cushman M. J Med Chem 60 3275-3288 (2017)
  20. Yeast Tdp1 regulates the fidelity of nonhomologous end joining. Bahmed K, Nitiss KC, Nitiss JL. Proc Natl Acad Sci U S A 107 4057-4062 (2010)
  21. Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison. He X, van Waardenburg RCAM, Babaoglu K, Price AC, Nitiss KC, Nitiss JL, Bjornsti MA, White SW. J Mol Biol 372 1070-1081 (2007)
  22. Real-time detection of TDP1 activity using a fluorophore-quencher coupled DNA-biosensor. Jensen PW, Falconi M, Kristoffersen EL, Simonsen AT, Cifuentes JB, Marcussen LB, Frøhlich R, Vagner J, Harmsen C, Juul S, Ho YP, Withers MA, Lupski JR, Koch J, Desideri A, Knudsen BR, Stougaard M. Biosens Bioelectron 48 230-237 (2013)
  23. A novel mechanism for the scission of double-stranded DNA: BfiI cuts both 3'-5' and 5'-3' strands by rotating a single active site. Sasnauskas G, Zakrys L, Zaremba M, Cosstick R, Gaynor JW, Halford SE, Siksnys V. Nucleic Acids Res 38 2399-2410 (2010)
  24. How similar are enzyme active site geometries derived from quantum mechanical theozymes to crystal structures of enzyme-inhibitor complexes? Implications for enzyme design. Dechancie J, Clemente FR, Smith AJ, Gunaydin H, Zhao YL, Zhang X, Houk KN. Protein Sci 16 1851-1866 (2007)
  25. New Hydrazinothiazole Derivatives of Usnic Acid as Potent Tdp1 Inhibitors. Filimonov AS, Chepanova AA, Luzina OA, Zakharenko AL, Zakharova OD, Ilina ES, Dyrkheeva NS, Kuprushkin MS, Kolotaev AV, Khachatryan DS, Patel J, Leung IKH, Chand R, Ayine-Tora DM, Reynisson J, Volcho KP, Salakhutdinov NF, Lavrik OI. Molecules 24 E3711 (2019)
  26. Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors. Nguyen TX, Abdelmalak M, Marchand C, Agama K, Pommier Y, Cushman M. J Med Chem 58 3188-3208 (2015)
  27. Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening. Lountos GT, Zhao XZ, Kiselev E, Tropea JE, Needle D, Pommier Y, Burke TR, Waugh DS. Nucleic Acids Res 47 10134-10150 (2019)
  28. Design and synthesis of fluorescent substrates for human tyrosyl-DNA phosphodiesterase I. Rideout MC, Raymond AC, Burgin AB. Nucleic Acids Res 32 4657-4664 (2004)
  29. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. Zhang XR, Wang HW, Tang WL, Zhang Y, Yang H, Hu DX, Ravji A, Marchand C, Kiselev E, Ofori-Atta K, Agama K, Pommier Y, An LK. J Med Chem 61 9908-9930 (2018)
  30. Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts. Brettrager EJ, van Waardenburg RCAM. Cancer Drug Resist 2 1153-1163 (2019)
  31. A tandem of SH3-like domains participates in RNA binding in KIN17, a human protein activated in response to genotoxics. le Maire A, Schiltz M, Stura EA, Pinon-Lataillade G, Couprie J, Moutiez M, Gondry M, Angulo JF, Zinn-Justin S. J Mol Biol 364 764-776 (2006)
  32. A tyrosyl DNA phosphodiesterase 1 from kinetoplastid parasite Leishmania donovani (LdTdp1) capable of removing topo I-DNA covalent complexes. Banerjee B, Roy A, Sen N, Majumder HK. Mol Microbiol 78 119-137 (2010)
  33. Structural basis for DNA 3'-end processing by human tyrosyl-DNA phosphodiesterase 1. Flett FJ, Ruksenaite E, Armstrong LA, Bharati S, Carloni R, Morris ER, Mackay CL, Interthal H, Richardson JM. Nat Commun 9 24 (2018)
  34. Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors. Lv PC, Agama K, Marchand C, Pommier Y, Cushman M. J Med Chem 57 4324-4336 (2014)
  35. Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore. Beck DE, Abdelmalak M, Lv W, Reddy PV, Tender GS, O'Neill E, Agama K, Marchand C, Pommier Y, Cushman M. J Med Chem 58 3997-4015 (2015)
  36. Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores. Weidlich IE, Dexheimer T, Marchand C, Antony S, Pommier Y, Nicklaus MC. Bioorg Med Chem 18 182-189 (2010)
  37. Novel group of tyrosyl-DNA-phosphodiesterase 1 inhibitors based on disaccharide nucleosides as drug prototypes for anti-cancer therapy. Komarova AO, Drenichev MS, Dyrkheeva NS, Kulikova IV, Oslovsky VE, Zakharova OD, Zakharova OD, Zakharenko AL, Mikhailov SN, Lavrik OI. J Enzyme Inhib Med Chem 33 1415-1429 (2018)
  38. Novel Semisynthetic Derivatives of Bile Acids as Effective Tyrosyl-DNA Phosphodiesterase 1 Inhibitors. Salomatina OV, Popadyuk II, Zakharenko AL, Zakharova OD, Fadeev DS, Komarova NI, Reynisson J, Arabshahi HJ, Chand R, Volcho KP, Salakhutdinov NF, Lavrik OI. Molecules 23 E679 (2018)
  39. Biochemical assays for the discovery of TDP1 inhibitors. Marchand C, Huang SY, Dexheimer TS, Lea WA, Mott BT, Chergui A, Naumova A, Stephen AG, Rosenthal AS, Rai G, Murai J, Gao R, Maloney DJ, Jadhav A, Jorgensen WL, Simeonov A, Pommier Y. Mol Cancer Ther 13 2116-2126 (2014)
  40. Novel Inhibitors of DNA Repair Enzyme TDP1 Combining Monoterpenoid and Adamantane Fragments. Mozhaitsev ES, Zakharenko AL, Suslov EV, Korchagina DV, Zakharova OD, Vasil'eva IA, Chepanova AA, Black E, Patel J, Chand R, Reynisson J, Leung IKH, Volcho KP, Salakhutdinov NF, Lavrik OI. Anticancer Agents Med Chem 19 463-472 (2019)
  41. Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites. Zhao XZ, Kiselev E, Lountos GT, Wang W, Tropea JE, Needle D, Hilimire TA, Schneekloth JS, Waugh DS, Pommier Y, Burke TR. Chem Sci 12 3876-3884 (2021)
  42. Tungstate as a Transition State Analog for Catalysis by Alkaline Phosphatase. Peck A, Sunden F, Andrews LD, Pande VS, Herschlag D. J Mol Biol 428 2758-2768 (2016)
  43. A Novel Class of Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Contains the Octahydro-2H-chromen-4-ol Scaffold. Li-Zhulanov NS, Zakharenko AL, Chepanova AA, Patel J, Zafar A, Volcho KP, Salakhutdinov NF, Reynisson J, Leung IKH, Lavrik OI. Molecules 23 E2468 (2018)
  44. Structure-function studies of a plant tyrosyl-DNA phosphodiesterase provide novel insights into DNA repair mechanisms of Arabidopsis thaliana. Kim H, Na SH, Lee SY, Jeong YM, Hwang HJ, Hur JY, Park SH, Woo JC, Kim SG. Biochem J 443 49-56 (2012)
  45. Structures of the phosphorylated and VO(3)-bound 2H-phosphatase domain of Sts-2. Chen Y, Jakoncic J, Parker KA, Carpino N, Nassar N. Biochemistry 48 8129-8135 (2009)
  46. Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavage. Comeaux EQ, Cuya SM, Kojima K, Jafari N, Wanzeck KC, Mobley JA, Bjornsti MA, van Waardenburg RC. J Biol Chem 290 6203-6214 (2015)
  47. An ensemble of structures of Burkholderia pseudomallei 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase. Davies DR, Staker BL, Abendroth JA, Edwards TE, Hartley R, Leonard J, Kim H, Rychel AL, Hewitt SN, Myler PJ, Stewart LJ. Acta Crystallogr Sect F Struct Biol Cryst Commun 67 1044-1050 (2011)
  48. New Hybrid Compounds Combining Fragments of Usnic Acid and Thioether Are Inhibitors of Human Enzymes TDP1, TDP2 and PARP1. Dyrkheeva NS, Filimonov AS, Luzina OA, Orlova KA, Chernyshova IA, Kornienko TE, Malakhova AA, Medvedev SP, Zakharenko AL, Ilina ES, Anarbaev RO, Naumenko KN, Klabenkova KV, Burakova EA, Stetsenko DA, Zakian SM, Salakhutdinov NF, Lavrik OI. Int J Mol Sci 22 11336 (2021)
  49. GPCR Modulation of Thieno[2,3-b]pyridine Anti-Proliferative Agents. Zafar A, Sari S, Leung E, Pilkington LI, van Rensburg M, Barker D, Reynisson J. Molecules 22 E2254 (2017)
  50. Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer. Hu DX, Tang WL, Zhang Y, Yang H, Wang W, Agama K, Pommier Y, An LK. J Med Chem 64 7617-7629 (2021)
  51. Human Tyrosyl-DNA Phosphodiesterase 1 Possesses Transphosphooligonucleotidation Activity With Primary Alcohols. Dyrkheeva N, Anarbaev R, Lebedeva N, Kuprushkin M, Kuznetsova A, Kuznetsov N, Rechkunova N, Lavrik O. Front Cell Dev Biol 8 604732 (2020)
  52. [Inhibitory Properties of Nitrogen-Containing Adamantane Derivatives with Monoterpenoid Fragments Against Tyrosyl-DNA Phosphodiesterase I]. Zakharenko AL, Ponomarev KU, Suslov EV, Korchagina DV, Volcho KP, Vasil'eva IA, Salakhutdinov NF, Lavrik OI. Bioorg Khim 41 731-736 (2015)
  53. Investigation into Improving the Aqueous Solubility of the Thieno[2,3-b]pyridine Anti-Proliferative Agents. Zafar A, Pilkington LI, Haverkate NA, van Rensburg M, Leung E, Kumara S, Denny WA, Barker D, Alsuraifi A, Hoskins C, Reynisson J. Molecules 23 E145 (2018)
  54. Measurement of the alcohol biomarker phosphatidylethanol (PEth) in dried blood spots and venous blood-importance of inhibition of post-sampling formation from ethanol. Beck O, Mellring M, Löwbeer C, Seferaj S, Helander A. Anal Bioanal Chem 413 5601-5606 (2021)
  55. The Human Tyrosyl-DNA Phosphodiesterase 1 (hTdp1) Inhibitor NSC120686 as an Exploratory Tool to Investigate Plant Tdp1 Genes. Macovei A, Pagano A, Sabatini ME, Grandi S, Balestrazzi A. Genes (Basel) 9 E186 (2018)
  56. UnTTrapping the ends: a new player in overcoming protein linked DNA damage. Bahmed K, Nitiss KC, Nitiss JL. Cell Res 20 122-123 (2010)
  57. Pre-steady state kinetics of DNA binding and abasic site hydrolysis by tyrosyl-DNA phosphodiesterase 1. Kuznetsov NA, Lebedeva NA, Kuznetsova AA, Rechkunova NI, Dyrkheeva NS, Kupryushkin MS, Stetsenko DA, Pyshnyi DV, Fedorova OS, Lavrik OI. J Biomol Struct Dyn 35 2314-2327 (2017)
  58. X-ray studies on ternary complexes of maltodextrin phosphorylase. Campagnolo M, Campa C, Zorzi RD, Wuerges J, Geremia S. Arch Biochem Biophys 471 11-19 (2008)
  59. Synthesis of 11-aminoalkoxy substituted benzophenanthridine derivatives as tyrosyl-DNA phosphodiesterase 1 inhibitors and their anticancer activity. Yang H, Wang FT, Wu M, Wang W, Agama K, Pommier Y, An LK. Bioorg Chem 123 105789 (2022)
  60. Decoupling of catalysis and transition state analog binding from mutations throughout a phosphatase revealed by high-throughput enzymology. Markin CJ, Mokhtari DA, Du S, Doukov T, Sunden F, Cook JA, Fordyce PM, Herschlag D. Proc Natl Acad Sci U S A 120 e2219074120 (2023)
  61. Identification of multidentate tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors that simultaneously access the DNA, protein and catalytic-binding sites by oxime diversification. Zhao XZ, Wang W, Lountos GT, Kiselev E, Tropea JE, Needle D, Pommier Y, Burke TR. RSC Chem Biol 4 334-343 (2023)
  62. Phosphonic acid-containing inhibitors of tyrosyl-DNA phosphodiesterase 1. Zhao XZ, Wang W, Lountos GT, Tropea JE, Needle D, Pommier Y, Burke TR. Front Chem 10 910953 (2022)
  63. Vanadate-based transition-state analog inhibitors of Cre-LoxP recombination. Martin SS, Wachi S, Baldwin EP. Biochem Biophys Res Commun 308 529-534 (2003)
  64. N-terminal domain of tyrosyl-DNA phosphodiesterase I regulates topoisomerase I-induced toxicity in cells. Brettrager EJ, Cuya SM, Tibbs ZE, Zhang J, Falany CN, Aller SG, van Waardenburg RCAM. Sci Rep 13 1377 (2023)


Related citations provided by authors (1)

  1. The Crystal Structure of Human Tyrosyl-DNA Phosphodiesterase, Tdp1. Davies DR, Interthal H, Champoux JJ, Hol WGJ Structure 10 237-248 (2002)

Quick links